Immunological aspects of recombinant factor VIIa (rFVIIa) in clinical use

Thrombosis and Haemostasis

Volumn 76, Issue 2, 1996, Pages 200-204

  Nicolaisen, Else Marie ^a   Hansen, Lisbeth Lyng ^a   Poulsen, Fritz ^a   Glazer, Steven ^a   Hedner, Ulla ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANTIBODY PRODUCTION; ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CONTROLLED STUDY; DRUG SAFETY; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0029836470     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650554     Document Type: Article

References (29)

1. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983; 71: 1836-41.
2. Hedner U, Glazer S, Pingel K, Alberts KA, Blombäck M, Shulman S, Johnsson H. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193 (letter).
3. Hedner U. Factor VIIa in the treatment of haemophilia. Blood Coagul Fibrinolysis 1990; 1: 307-17.
4. Hedner U, Glazer S. Management of Hemophilia patients with inhibitors. Hematology/Oncology Clinics of North America 1992; 6: 1035-46.
5. Hedner U, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfus Med Rev 1993; 7: 78-83.
6. Macik GB, Hohneker J, Roberts HR, Griffen AM. Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor. Am J Hematol 1989; 32: 232-4.
7. Majumdar G, Savidge, GF. Recombinant factor VIIa for intracranial haemorrhage in a Jehovah's witness with severe haemophilia A and factor VIII inhibitors. Blood Coagul Fibrinolysis 1993; 4: 1031-3.
8. Majumdar G, Phillips JK, Lavallee H, Savidge, GF. Acquired haemophilia in association with type III von Willebrand's disease: successful treatment with high purity von Willebrand's factor and recombinant factor VIIa. Blood Coagul Fibrinolysis 1993; 4: 1035-7.
9. O'Marcaigh AS, Schmaltz BJ, Shaughnessy WJ, Gilchrist GS. Successful Hemostasis during a major orthopedic operation by using recombinant activated factor VII in a patient with severe hemophilia A and a potent inhibitor. Mayo Clin Proc 1994; 69: 641-4.
10. Schmidt ML, Gamerman S, Smith HE, Scott JP, Di Michele DM. Recombinant Activated Factor VII (rFVIIa) Therapy for Intracranial Hemorrhage in Hemophilia A Patients with Inhibitors. Am J Hematol 1994; 47: 36-40.
11. Stubbs JR, Uzel CS, Baker SL, Martino RL. Peripartum use of recombinant factor VIIa in inherited factor VII deficiency. Transfusion 1994; 34: S121, (abstr).
12. Di Michele D. Patients treated on a compassionate use basis - case stories. Hemophilia B. In: 2nd Symposium on New Aspects of Hemophilia Treatment. Hedner U, Roberts HR, eds. Medicom 1991; pp 130-2.
13. Bergman F, Hoyer PF, Barthels M. Rescue treatment with recombinant factor VIIa (rFVIIa) in a hemophilia B patient with inhibitor. Annals of Hematology 1995; 70 (Suppl. 1 ): A37 (abstr).
14. Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer G, Hedner U. Measurement of basal levels of factor VIIa in Hemophilia A and B patients. Blood 1992; 80: 25-8.
15. Macik BG, Lindley CM, Lusher J, Sawyer WT, Bloom AL, Harrison IF, Baird-Cox K, Birch K, Glazer S, Roberts HR. Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): Results of a phase I study. Blood Coagul Fibrinolysis 1993; 4: 521-7.
16. Lusher JM. rFVIIa Results of a double-blind dose finding study. Transfusion 1994; 34: 728, (abstr).
17. Glazer S. Recombinant activated factor VII - Safety and efficacy. Transfusion 1994; 34: 728, (abstr).
18. Ukkonen P, Korpela J, Suni J, Hedman K. Inactivation of Human Immunodeficiency Virus in Serum Specimens as a Safety Measure for Diagnostic Immunoassays. Eur J Clin Microbiol Infect Dis 1988; 7: 518-23.
19. Bech RM, Nicolaisen EM, Andersen PM, Glazer S, Hedner U. Recombinant FVIIa for the treatment of congenital factor VII deficient patients. Thromb Haemost 1995; 73: 983 (abstr).
20. Fort JA. An infant with FVII deficiency. In: 2nd Symposium on New Aspects of Hemophilia Treatment. Hedner U, Roberts HR, eds. Medicom 1991; pp 142-3.
21. Richards SM, Olson TA, McPherson JM. Antibody Response in Patients With Gaucher Disease After Repeated Infusion With Macrophage-Targeted Glucocerebrosidase. Blood 1993; 82: 1402-9.
22. Roberts HR, Hoffman M. Hemophilia and Related Conditions-Inherited Deficiencies of Prothrombin (Factor II), Factor V, and Factors VII to XII. In: Williams Hematology, Fifth Edition. Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. New York, MacGraw-Hill 1995; p 1431.
23. Delmer A, Horellou M-H, Andreu G, Lecompte T, Rossi F, Kazatchkine MD, Samana M, Zittoun R. Life-Threatening Intracranial Bleeding Associated with the presence of an antifactor VII autoantibody. Blood 1989; 74: 229-32.
24. Campbell E, Sanal S, Mattson J, Walker L, Estry S, Mueller L, Schwartz M, Hampton S. Factor VII Inhibitor. Am J Med 1980; 68: 962-4.
25. Raucourt E, Dumont MD, Tourani JM, Hubsch JP, Riquet M, Fisher AM. Acquired factor VII deficiency associated with pleural liposarcoma. Blood Coagul Fibrinolysis 1994; 5: 833-6.
26. Weisdorf D, Hasegawa D, Fair DS. Acquired factor VII deficiency associated with aplastic anaemia: correction with bone marrow. Br J Haematol 1989; 71: 409-13.
27. Thim L, Bjørn S, Christensen M. Nicolaisen EM, Lund-Hansen T, Pedersen A, Hedner U. Amino acid sequence and post-translational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 1988; 27: 7785-93.
28. Thompson RJ, Jackson AP, Langlois N. Circulating antibodies to mouse immunoglobulins in normal subjects-inci dence, species specificity, and effects on two-site assay for creatine kinase-MB isoenzyme. Clin Chem 1986; 32: 476-81.
29. Bray GL, Kazemi M, Liu S-L, Courter S, Buckwalter C, White III G, Gomperts ED and the Recombinate® Study Group. Results of foreign protein antibody (AB) ELISAs in a cohort of recombinant FVIII (r-FVIII) treated patients. Blood 1994; 84: 65a (Suppl 1) (abstr).